The rest of the 100 (in alphabetical order): Richard Riggs, Saudi Aramco Energy Ventures
Month: January 2019
GCV Rising Stars Awards 2019: Michael Remmes
The rest of the 100 (in alphabetical order): Michael Remmes, State Farm Ventures
GCV Rising Stars Awards 2019: Daniel Gulati
The rest of the 100 (in alphabetical order): Daniel Gulati, Comcast Ventures
GCV Rising Stars Awards 2019: Egor Abramov
The rest of the 100 (in alphabetical order): Egor Abramov, Fort Ross Ventures
GCV Rising Stars Awards 2019: Rohen Sood
The rest of the 100 (in alphabetical order): Rohen Sood, Reinventure
GCV Rising Stars Awards 2019: Charles Kunsch
The rest of the 100 (in alphabetical order): Charles Kunsch, AbbVie Ventures
GCV Rising Stars Awards 2019: Ludovic Copéré
The rest of the 100 (in alphabetical order): Ludovic Copéré, Sony Innovation Fund
GCV Rising Stars Awards 2019: Amit Aysola
The rest of the 100 (in alphabetical order): Amit Aysola, Wanxiang Healthcare Investments
Jusda gets $356m series A delivery
The end-to-end supply chain services provider, which was spun off from Foxconn, has raised $356m in a China Life-led round that also featured China Railway Group.
Lilly Asia Ventures lands $100m for Fund V
US-based pension fund Lacera has provided $100m for the latest fund to be raised by corporate venturing unit Lilly Asia Ventures, which has a $750m target.
Comcast grows Acorns in $105m series E
Comcast subsidiaries Comcast Ventures and NBCUniversal both invested in the financial management app developer, bringing its valuation up to $860m.
Alibaba gets in Sandbox for $68m round
Virtual reality entertainment operator Sandbox VR has amassed $68m in series A capital from investors including Alibaba.
Taimei passes series E trial with $80m
Existing backer SoftBank China was among the participants in a series E round that will support the expansion of Taimei Technology’s clinical trial management platform.
Hana Financial hits the venture capital space
Hana Ventures intends to provide some $890m in loans and direct investment for VC firms targeting biotech and ICT companies, over the next three years.